nChroma Bio
nChroma Bio is a genetic medicines company developing programmable in vivo delivery technologies combined with gene-regulating cargos to create targeted, durable therapies. The company focuses on liver-directed and extrahepatic delivery approaches and is advancing an epigenetic editing lead candidate for chronic hepatitis B through preclinical and CTA-enabling studies.
Industries
biotechnology
medical
product-research
Nr. of Employees
medium (51-250)
Products
CRMA-1001
A liver-directed epigenetic editor delivered via lipid nanoparticles designed to durably silence hepatitis B virus (targeting cccDNA and integrated HBV DNA) using methylation-based epigenetic modulation without DNA cutting.
CRMA-1001
A liver-directed epigenetic editor delivered via lipid nanoparticles designed to durably silence hepatitis B virus (targeting cccDNA and integrated HBV DNA) using methylation-based epigenetic modulation without DNA cutting.
Services
Strategic collaboration and partnership development
Partnering to apply modular delivery solutions and genetic cargos to joint discovery and development programs.
Strategic collaboration and partnership development
Partnering to apply modular delivery solutions and genetic cargos to joint discovery and development programs.
Expertise Areas
- Epigenetic editing and gene regulation
- In vivo targeted delivery
- Liver-directed therapeutics
- Extrahepatic delivery using engineered particles
Key Technologies
- Lipid nanoparticles (LNPs)
- Engineered virus-like particles (eVLP/DLVR)
- Epigenetic editors (DNA methylation-based)
- Ribonucleoprotein (RNP) delivery of gene editors (base editors, prime editors, CRISPR/Cas)